Upper Gastrointestinal (lips to ileocecal valve, including esophagus and stomach)
Jonathan C. Salo, MD (he/him/his)
Surgical Oncologist
Levine Cancer Institute
Charlotte, North Carolina, United States
Van C. Sanderfer, MD
Resident
Atrium Health
Charlotte, North Carolina, United States
Alexis Holland, MD
Resident
Atrium Health, United States
Erin Donahue, PhD
Senior Biostatistician
Levine Cancer Institute, United States
Reilly Shea, CCRP
Oncology Research Coordinator
Levine Cancer Institute
Charlotte, North Carolina, United States
Reilly Shea, CCRP
Oncology Research Coordinator
Levine Cancer Institute
Charlotte, North Carolina, United States
Ella Schwarzen, n/a
Summer Intern
Levine Cancer Institute, United States
Nicholas Mullis, n/a
Summer Intern
Levine Cancer Institute, United States
Sophia Bellavia, n/a
Summer Intern
Levine Cancer Institute, United States
Kunal Kadakia, MD
Medical Oncologist
Levine Cancer Institute, United States
Jonathan C. Salo, MD (he/him/his)
Surgical Oncologist
Levine Cancer Institute
Charlotte, North Carolina, United States
Our retrospective study demonstrated that for low-risk patients with adenocarcinoma of the esophagus, there is a survival benefit to the addition of surgery. Conversely, we failed to detect a survival benefit to the addition of surgery in the highest-risk quartile of patients. Measurement of body composition may help identify a high-risk subset of patients with locally-advanced adenocarcinoma of the esophagus who may benefit from forgoing surgery after chemoradiation.